-
MEI Pharma (MEIP) Completes 10M Common Offering
-
MEI Pharma (MEIP) Prices 10M Share Offering at $4/Share
-
Roth Capital Adds MEI Pharma (MEIP) to Focus List; Multiple Key Inflection Points Coming
-
Roth Affirms 'Buy' Rating on MEI Pharma (MEIP); New AML Treatment Data Bolsters Confidence
-
Roth Positive on MEI Pharma (MEIP) Following ME-344 Phase 1b Initiation
-
Streetinsider.com's Hot Lunchtime Reads 04/07: (KR) (MSFT) (SRPT) (MDVN)
-
Pre-Clinical Data for MEI Pharma's (MEIP) Pracinostat Will Set Development Tone - Roth Capital
-
MEI Pharma (MEIP) Prices 4.38M Common Offering at $8/Share